Known targets — ChEMBL curated mechanism
AGTR1DHFRGABBR1GABBR2GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGARTNR3C2PBP2XPTGS1PTGS2VKORC1blablaT-3blaT-4blaT-5blaT-6dacAdacBdacCfolAftsImrcAmrcBmrdApbp1apbp1bpbp2apbp2bpbp3polthyA
The experimentally established mechanism targets of Potassium Ion. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 12/20 | 0.58 |
| ▸ | ACACB | O00763 | 4/20 | 0.53 |
| ▸ | LIPG | Q9Y5X9 | 4/20 | 0.40 |
| ▸ | LPL | P06858 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1410340 | 0.89 | NOTUM (0.64) | NOTUMACACBLIPGLPL | |
| SCHEMBL1410269 | 0.86 | NOTUM (0.59) | NOTUM | |
| SCHEMBL21624804 | 0.80 | NOTUM (0.63) | NOTUMACACB | |
| SCHEMBL21624800 | 0.80 | NOTUM (0.63) | NOTUMACACB | |
| SCHEMBL1410436 | 0.79 | NOTUM (0.58) | NOTUMACACBLIPGLPL | |
| SCHEMBL1410172 | 0.78 | LIPG (0.53) | ACACBLIPGLPL | |
| Potassium Ion SCHEMBL1410626 | 0.78 | NOTUM (0.58) | NOTUMLIPGLPL | |
| Potassium Ion SCHEMBL1410609 | 0.78 | LIPG (0.56) | LIPGLPL | |
| SCHEMBL12210031 | 0.77 | NOTUM (0.65) | NOTUM | |
| SCHEMBL1409550 | 0.76 | NOTUM (0.45) | NOTUMLIPGLPL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110251187-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-10-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110251187-A1 | HETEROCYCLIC COMPOUND | NES, BMI1, DOT1L | NOTUM 874/4885ACACB 1733/4885LIPG 3938/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.